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a b s t r a c t
Background: Fibroblast growth factor 23 (FGF23) is known to cause left ventricular hyper-
trophy (LVH), but controversy exists concerning its effect in dialysis. This study evaluated
associations between FGF23 levels, echocardiography and prognosis in patients on
hemodialysis (HD).
Methods: Patients >18 years on chronic HD were included in this cross-sectional study.
Plasma C-terminal FGF23 concentration was measured with ELISA and transthoracic
echocardiography was performed, both before and after HD treatment.
Results: 239 haemodialysis (HD) patients were included in the study. The FGF23 was
median 3560RU/ml (IQR 1447–9952). The mean left ventricular mass index (LVMI) was
110.2±26.7 g/m2 and the left ventricular ejection fraction (LVEF) was 52.7±9.9%. Deﬁned
by LVMI, LVH was found in 110 patients (46%), of which 92 (84%) had hypertension (p<0.01).
Patients with LVH had FGF23 levels of 5319 RU/ml (IQR 1858–12,859) and those without
2496 RU/ml (IQR 1141–7028) (p<0.01). FGF23 was signiﬁcant positive correlated with LVMI
(p<0.01), and negatively to LVEF (p<0.01). In a multivariate analysis, FGF23 was correlated
with LVEF (p<0.01), but onlymarginally to LVMI (p<0.01). Cardiovascular events in the follow
up period was not correlated with FGF23. Furthermore, FGF23 was independently correlated
with overall mortality (p<0.001).
Conclusion: FGF23 was positively correlated with LVH and negatively to LVEF. FGF23 was an
independent predictor for overall mortality.© 2019 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
∗ Corresponding author.
E-mail address: tureln@gmail.com (T.L. Nielsen).
https://doi.org/10.1016/j.nefro.2018.10.007
0211-6995/© 2019 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
nefrolog ia 2019;39(3):258–268 259
El FGF23 en pacientes en hemodiálisis se asocia con hipertroﬁa
ventricular izquierda y fracción de eyección reducida
Palabras clave:
Factor de crecimiento
ﬁbroblástico 23
Hipertroﬁa ventricular izquierda
Fracción de eyección ventricular
izquierda
Diálisis
Enfermedad renal terminal
Ecocardiografía
Fosfato
Hormona paratiroidea
r e s u m e n
Antecedentes: Se sabe que el factor de crecimiento ﬁbroblástico 23 (FGF23) provoca hipertroﬁa
ventricular izquierda (HVI), pero existe controversia sobre su efecto en la diálisis. Este estu-
dio evaluó las asociaciones entre los niveles del FGF23, la ecocardiografía y el pronóstico en
pacientes en hemodiálisis (HD).
Métodos: Se incluyeron pacientes >18 an˜os con HD crónica en este estudio transversal. La
concentración del FGF23 en el extremo C del plasma se midió con ELISA y se realizó una
ecocardiografía transtorácica, antes y después del tratamiento de HD.
Resultados: Se incluyeron 239 pacientes en HD en el estudio. El FGF23 tenía una mediana de
3.560RU/ml (amplitud intercuartílica: 1.447-9.952). El índice de masa ventricular izquierdo
(IMVI) medio fue de 110,2±26,7 g/m2 y la fracción de eyección del ventrículo izquierdo
(FEVI) fue del 52,7±9,9%. Deﬁnida por el IMVI, la HVI se localizó en 110 pacientes (46%),
de los cuales 92 (84%) presentaban hipertensión (p<0,01). Los pacientes con HVI presen-
taron niveles del FGF23 de 5.319RU/ml (amplitud intercuartílica: 1.858-12.859) y aquellos
sin 2.496RU/ml (amplitud intercuartílica: 1.141-7.028) (p < 0,01). El FGF23 fue considerable-
mente positivo correlacionado con el IMVI (p<0,01) y negativo con la FEVI (p<0,01). En un
análisis multivariante, el FGF23 se correlacionó con la FEVI (p<0,01), pero solo marginal-
mente con el IMVI (p<0,01). Los episodios cardiovasculares en el período de seguimiento
no se correlacionaron con el FGF23. Además, el FGF23 se correlacionó independientemente
con la mortalidad general (p < 0,001).
Conclusión: El FGF23 se correlacionó positivamente con la HVI y negativamente con la FEVI.
El FGF23 fue un factor independiente para la mortalidad general.
© 2019 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
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atients treated with chronic hemodialysis (HD) or peritoneal
ialysis (PD) due to end stage renal disease (ESRD) have a mas-
ively increased risk of cardiovascular disease (CVD).1 The risk
s increased by a factor of 100 in younger patients, compared
o the general population.2 CVD in uremia is characterized
y Mönckeberg arteriosclerosis with medial calciﬁcation,3
ardiac ﬁbrosis, left ventricular hypertrophy (LVH), diastolic
ysfunction and progressive heart failure (HF).2 Common
auses of LVH are volume overload, hypertension and an
ncreased pulse pressure secondary to arterial calciﬁcation,
ith consequent accelerated pulse wave velocity. A newly dis-
overedhormone, ﬁbroblast growth factor 23 (FGF23), has been
hown to have an, apparently klotho-independent,4,5 direct
ffect on the heart. FGF23’s primary function is to increase
enal excretion of phosphate, with klotho acting as a co-factor.
proposed mechanism for FGF23’s effect on the heart is the
ctivation of FGF receptor-4 on cardiac myocytes to stimu-
ate phospholipase C/calcineurin-nuclear factor of activated
cell signaling.6
FGF23 ismassively elevated in ESRDpatients onHD,7 by the
eedback mechanism of intractable hyperphosphatemia, and
eﬁciency of the necessary co-factor klotho.8 FGF23 indepen-
ently causes LVH in rodents5 and is associatedwith LVH, both
nnon-uremic subjects9–13 and in patientswith chronic kidney
isease (CKD).11,13–15 The relationship is less clear for patientsby-nc-nd/4.0/).
with ESRD. While two studies, by Hsu et al. in HD patients16
and Sarmento-Dias et al. in PD patients,17 showed a positive
relation, three other studies, failed to ﬁnd a relationship.11,18,19
Systolic function has received less attention, but shows a sim-
ilar picture. A relationship between FGF23 and prevalent or
later heart failure (HF) is seen in non-uremic11,12,20,21 and CKD
patients.11,22,23 Only two studies have addressed this question
for ESRD patients11,16; neither found any relationship.
Other cardiovascular associations of FGF23 include
increased arterial stiffness and atherosclerosis in rodents,24
non-uremic subjects25,26 and CKD,27 with a consequent
increase in pulse pressure.24,28 FGF23 is associated with
an increased risk of cardiovascular events and/or death
in rodents,29 non-uremic patients,30,31 and CKD.22,23,31–34
Theoretical pathogenic mechanisms for this association
exist. FGF23 is induced by renin-angiotensin-aldosterone
system activation and promotes pro-ﬁbrotic crosstalk
between cardiac myocytes and ﬁbroblasts in CKD patients.35
Calcitriol deﬁciency is almost universal in CKD; calcitriol
treatment in uremic rats attenuates cardiac FGF23/FGFR4
and hypertrophy36 As previously mentioned, confusion exists
concerning the effect of FGF23 on prognosis in ESRD patients.
A relationship to death has7,37 and has not38 been found; a
relationship to subsequent cardiovascular events was seen in
one study,39 but not in another.33
The existence of detailed echocardiographic information
for a large number of HD patients permits a deﬁnitive answer
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to the relationship between FGF23 and heart function and
prognosis in ESRD. We hypothesized that FGF23 was related
to LVH, a reduced left ventricular ejection fraction (LVEF), and
an increased risk of death and cardiovascular events in HD
patients.
Methods
Patients
This cross-sectional study included patients from two dialy-
sis centers between January and April 2014. Inclusion criteria
were clinically stable patients aged 18 years or older on chronic
maintenance HD for more than 2 weeks who were able to give
their written informed consent. At inclusion all patients had
blood samples collected and transthoracic echocardiography
performed before and after a single routine HD treatment.
Patient demographics, comorbidity, treatment and bio-
chemistry datawere obtained fromhospitalmedical ﬁles. Vital
parameters (bloodpressure (BP) andheart rate (HR))weremea-
sured at the beginning of HD treatment. All-cause mortality,
cause of death, cardiovascular events (de novo HFrEF, lung
embolus, acute myocardial infarction, endocarditis, arrhyth-
mias and sudden cardiac death) and time to ﬁrst admission
was assessed from medical ﬁles (OPUS Arbejdsplads, version
2.5.0.0 ©2010 Computer Sciences Corporation (CSC) and Epic,
Sundhedsplatformen ©2016 Epic Systems Corporation). Data
for drug treatment for chronic kidney disease – mineral bone
disorder (CKD-MBD) were incomplete, and could not be sup-
plemented due to changes in the electronic patient ﬁles.
Patients were followed until death or 1.1.2017. Time to ﬁrst
cardiovascular event (cardiovascular death,myocardial infarc-
tion, heart failure, cardiovascular operation) was registered.
Some of the data presented in this paper has been
used to address another question, and has been published
previously.40
Patients were receiving routine HD treatment on Gambro
machines (ArtisTM Dialysis System) using synthetic high ﬂux
ﬁlters >1.6m2, Polyamix
®
(210H or 170H Gambro Polyﬂux
®
)
and Polysulfone (Fresenius FX 100, FX 80 or FX 50) ﬁlters.
FGF23 measurement
Blood sampleswere collected fromall patients from the arteri-
ovenous ﬁstula or the dialysis catheter before a single routine
dialysis session and directly after centrifuged for 10min at
3000 rpm at 20 ◦C. Plasma was stored at −80 ◦C in cryotubes
until analysis. Plasma levels of standard biochemistry such as
CRP, hemoglobin and creatinine were measured by the local
clinical laboratory using standard methods (Siemens Dimen-
sion Vista 1500). Plasma concentrations of FGF23 (C-Term)
were measured with a commercial available 2nd genera-
tion two-site immunosorbent assay (ELISA; Immutopics Inc.,
Santa Clemente, CA, USA) in January 2017. The assay used
streptavidin-coated microplate wells, a biotinylated human
FGF23 antibody and a horseradish peroxidase conjugated
human FGF23 antibody. The bound enzyme activity was
detected with tetramethylbenzidine (TMB) as substrate. The
detection limit was 1.5RU/ml (assay sensitivity), and the39(3):258–268
intra-assay coefﬁcients of variation were 2.4% (at 33.7RU/ml)
and 1.4% (at 302RU/ml). The inter-assay coefﬁcient of varia-
tion was 4.7% (at 33.6RU/ml) and 2.4% (at 293RU/ml). FGF23 is
stable for 40months in plasma samples stored at−80 ◦C.41 The
reference range of FGF23 used was mean±SD, 129±33RU/ml.
Echocardiography
Transthoracic echocardiography was performed on GE
machines (Vivid S6) by three skilled echocardiographers
before and after HD treatment. The examinations were then
analyzed in GE software (GE Healthcare EchoPAC v113.1.3 R3)
and revised by consultants in cardiology. LVH was deﬁned
as left ventricular mass index (LVMI) >115 g/m2 for men and
>95g/m2 for women after the Devereux formula indexed for
Body Surface Area (BSA).42,43 Simpson’s biplane method was
used for calculating LVEF biplane.44,45 HFrEF was deﬁned as
LVEF <40%.
Statistics
Normally distributed variableswere compared using student’s
t-test and MANOVA. Where relevant, logarithmic transforma-
tion was performed. Non-normally distributed variables were
compared using Mann–Whitney U test and categorical anal-
ysis using Chi-square test. FGF23 values were divided into
approximate quartiles for analysis. Pearson regression anal-
ysis was used for correlation. A probability of p<0.05 was
considered signiﬁcant. Signiﬁcance values were classiﬁed as
p<0.05, p<0.01, p<0.001and as non-signiﬁcant (NS) at p>0.05.
Kaplan Meier and Cox proportional hazards backward step-
wise analysis was performed on follow-up data in order to
identify risk factors for death and cardiac events.
Ethics
The study was performed in accordance with the Helsinki
Declaration II and was approved by the The Danish National
Committee on Research Ethics (H-3-2013-098) and the Danish
Data Protection Agency, Copenhagen (HIH2013-027).
Results
239 HD patients were included in the study. Patient details
are shown in Table 1. Patients had median 3560RU/ml
FGF23 plasma concentrations (IQR 1447-9952). Mean LVMI was
110.2±26.7 g/m2. Mean septal and posterior wall thickness
were 1.12±0.17 cm and 1.09±0.15 cm respectively, and mean
LVIDd was 2.64±0.40 cm/m2. The LVEF was 52.7±9.9%. 27
(12%) had echocardiographic HFrEF. Deﬁned by Devereux for-
mula for LVMI, LVH was found in 110 patients (46%), where
92 (84%) had hypertension (p<0.05). Patients with LVH had a
median FGF23 plasma concentrations 5319RU/ml FGF23 (IQR
1858–12,859) and those without 2496RU/ml (IQR 1141–7028)
(p<0.01).Correlations to FGF23 are shown inTable 2 and Fig. 1.Where
LVMI was positively and LVEF was negatively correlated with
FGF23 (Fig. 1). High FGF23 levels were associated with markers
of increasing uremia (dialysis ultraﬁltration, ESRD duration,
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Table 1 – Baseline characteristics, n=239.
Clinical
Age (years) 65.6±14.2
Female, n (%) 74 (31%)
Height (cm) 172±10
Weight (kg) 75.7±17.5
Body mass index (kg/m2) 25.5±5.5
ESRD duration (years) 3.3 (1.5–6.7)
HD duration (years) 2.6 (1.2–5.9)
Previous PD, n (%) 59 (25%)
Smoker (present/previous), n (%) 53/95 (22%/40%)
Diuresis (L) 0.4 (0–1.1)
Comorbidity
Ischemic heart disease, n (%) 78 (33%)
Myocardial infarction, n (%) 43 (18%)
NYHA class III–IV, n (%) 45 (19%)
Previous cardiac surgery, n (%) 49 (21%)
Cerebrovascular disease, n (%) 51 (21%)
Peripheral vascular disease, n (%) 66 (28%)
Diabetes, n (%) 81 (34%)
Cancer, n (%) 64 (27%)
Previous renal transplant(s), n (%) 13 (5%)
Renal diagnosis
Glomerulonephritis, n (%) 31 (13%)
Chronic interstitial nephropathy, n (%) 27 (11%)
Polycystic disease, n (%) 22 (9%)
Hypertensive, n (%) 62 (26%)
Diabetic nephropathy, n (%) 47 (20%)
Other, n (%) 29 (12%)
Unknown, n (%) 21 (9%)
Medication
Diuretic, n (%) 117 (49%)
-blocker, n (%) 133 (56%)
Calcium channel antagonist, n (%) 92 (38%)
Angiotensin receptor antagonist, n (%) 23 (10%)
Angiotensin converting enzyme inhibitor, n (%) 30 (13%)
Other antihypertensive, n (%) 32 (13%)
Total antihypertensive, n (%) 183 (77%)
Statins, n (%) 94 (39%)
Calcium carbonate, n (%) 63 (50%)
Sevelamer, n (%) 52 (41%)
Lanthanum, n (%) 19 (15%)
Any phosphate binder, n (%) 101 (81%)
Alfacalcidol, n (%) 87 (70%)
Cinacalcet, n (%) 16 (12%)
Dialysis
Hemodiaﬁltration, n (%) 74 (31%)
Dialysis duration (minutes) 221±28
Fistula access, n (%) 159 (67%)
Ultraﬁltration (L) 1.99±1.16
Systolic BP (mm Hg) 144±21
Diastolic BP 77±14
Pulse pressure 67±18
Biochemistry
Hemoglobin (mM) 7.0±0.9
Ionized calcium (mM) 1.18±0.13
Phosphate (mM) 1.52±0.43
PTH (pM) 23.2 (13.1–38.5)
25-hydroxycholecalciferol (M) 74.1±27.3
FGF23 (RU/ml) 3559 (1447–9951)
Albumin (g/L) 35.2±5.0
Table 1 – (Continued)
Transferrin (mM) 22.6±5.4
Creatinine (M) 687±251
CRP (mg/L) 5 (3–15)
Values expressed in numbers (percentage), mean± standard devi-
ation (SD) or median (interquartile range (IQR)). ESRD=end
stage renal disease; HD=hemodialysis; PD=peritoneal dialy-
sis; NYHA=New York Heart Association; BP=blood pressure;
PTH=parathyroid hormone; FGF23=ﬁbroblast growth factor 23;
CRP=C-reactive protein.
p-creatinine, lowdiuresis and lowdiuretic use). Theywere also
correlated with use of -blockers, sevelamer and cinacalcet,
diastolic blood pressure, p-phosphate, p-PTH, and C-reactive
protein (CRP). They were negatively associated with presence
of diabetic nephropathy. No correlation to prevalent cardio-
vascular disease was seen. LVMI and LVEF were negatively
correlated (Fig. 2).
FGF23 was positively correlated with interventricular sep-
tum end diastolic diameter (IVSd), left ventricular posterior
wall end diastolic diameter (LVPWd), LVMI, left atrium end
diastolic volume (LAEDV), and negatively to LVEF. There were
no signiﬁcant correlations to LVIDd, mitral valve E/A ratio (MV
E/A), mitral valve E/é ratio (MV E/é), global longitudinal strain
(GLS) or tricuspid regurgitation peak gradient (TR maxPG).
Patientswith an FGF23 >10,000RU/mlhada LVMI 17g/m2 (17%)
greater than patients <1500RU/ml and a LVEF that was 6 per-
cent points (11%) lower.
Univariate and multivariate correlations to patient death
and cardiovascular event risk are shown in Table 3. Therewere
89 deaths (37%) and 63 (26%) cardiovascular events: endocardi-
tis 7, cardiac valve operation 2, peripheral vascular operation
12, cardiac vascular operation 6, myocardial infarction 6, de
novo HFrEF (LVEF <40% described in the patient records) 16
and cardiovascular death 14. FGF23, but not LVMI was signiﬁ-
cantly correlated with patient survival (Fig. 3). While patients
without echocardiographic HFrEF had similar patient survival
rates regardless of LVEF (2-year survival 76%), but patients
with HFrEF had signiﬁcantly lower survival (48%, p<0.05).
Adjusted mortality risk ratios for FGF23 groups compared to
FGF23 <1500 RU/ml were: FGF23 1500–4000RU/ml 1.85 (95%
CI 0.99–3.45, NS); 4000–10,000RU/ml 3.00 (1.46–6.13, p<0.01);
>10,000RU/ml 3.76 (1.98–7.14, p<0.001). Independent risk fac-
tors for mortality were age, p-creatinine (protective), CRP and
FGF23. Independent risk factors for cardiovascular eventswere
CRP, LAEDV index and global longitudinal strain (GLS). Dif-
ferences between the correlations to patient mortality and
cardiovascular even riskwere noted. Patientmortalitywas pri-
marily related to clinical and biochemical variables, whereas
cardiovascular riskwas primarily related to echocardiographic
ﬁndings, previous cardiovascular disease, and markers of
inﬂammation (CRP, ferritin) and malnutrition (low transfer-
rin). FGF23 was not associated to cardiovascular event risk. 37
(15%) patients developed arrhythmias, primarily atrial ﬁbrilla-
tion. There was no relationship between FGF23 and prevalent
or incident arrhythmia.
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Table 2 – Relationship of FGF23 to clinical, biochemical and echocardiographic variables. Data for non-signiﬁcant clinical
(32 variables)* and biochemical variables (5 variables)* not shown.
Quartile 1 2 3 4 Sig.
FGF23 range (RU/ml) <1500 1500–4000 4000–10,000 >10,000
n=62 n=67 n=51 n=59
Diabetic nephropathy 18 (30%) 12 (18%) 7 (16%) 8 (14%) <0.05
Average ultraﬁltration (L) 1.05 (0.4–2.0) 1.9 (1.0–3.0) 2.1 (1.6–3.0) 2.6 (1.5–3.4) <0.001
Diuresis (L) 1.05 (0.48–1.83) 0.30 (0.0 –0.90 0.13 (0.0–1.00) 0 (0–0.60) <0.001
ESRD duration (years) 2.4 (1.1–4.0) 3.3 (0.9–7.3) 3.7 (1.7–7.0) 4.4 (2.7–7.2) <0.01
Diuretic, n (%) 46 (74%) 27 (40%) 23 (45%) 21 (36%) <0.001
-blocker, n (%) 29 (47%) 33 (49%) 17 (67%) 37 (63%) <0.05
Sevelamer, n (%) 7 (21%) 11 (32%) 11 (44%) 23 (70%) <0.001
Cinacalcet, n (%) 0 (0%) 3 (8%) 6 (23%) 7 (20%) <0.01
Diastolic BP (mmHg) 72±11 69±13 75±13 77±14 <0.01
Biochemistry
FGF23 (RU/ml) 827 (519–1091) 2353 (1869–3078) 5272 (1625–7969) 18,542 (14,822–20,765) <0.001
Phosphate (mM) 1.34±0.31 1.40±0.34 1.64±0.48 1.72±0.45 <0.001
PTH (pM) 21.6 (9.2–33.1) 20.5 (11.8–34.0) 21.7 (14.6–37.7) 30.9 (17.0–54.1) =0.06
Creatinine (M) 565±236 665±203 766±233 776±277 <0.001
CRP (mg/L) 3.5 (3–10) 5 (3–17) 5.5 (3–10) 7 (3–25) <0.05
Echocardiography
IVSd (cm) 1.08±0.13 1.12±0.17 1.14±0.17 1.15±0.18 <0.05
LVPWd (cm) 1.06±0.13 1.08±0.15 1.11±0.15 1.13±0.17 <0.05
LVIDd (cm) 4.80±0.6 4.89±0.68 4.98±0.60 5.01±0.71 NS
LVIDd index (cm/m2) 2.58±0.35 2.66±0.45 2.67±0.38 2.66±0.41 NS
LV dilatation, n (%) 3 (5%) 6 (9%) 7 (14%) 7 (12%) NS
LVPWd (cm) 1.06±0.13 1.08±0.15 1.11±0.15 1.13±0.17 <0.05
LVM (g) 189±47 201±49 214±52 225±63 <0.001
LVM Index (g/m2) 101±22 109±28 114±25 118±29 <0.001
LVH, n (%) 20 (33%) 27 (40%) 28 (56%) 35 (60%) <0.01
LAEDV Index (ml/m2) 30.4±8.5 36.6±15.3 34.5±12.5 39.5±14.3 <0.01
MV E/A ratio 0.96±0.29 1.12±0.58 1.11±0.52 1.26±0.88 NS
E/é ratio 9.6±4.2 11.0±6.4 11.8±6.9 11.4±6.2 NS
LVEF biplane (%) 55.4±9.1 51.6±10.0 54.7±8.2 49.4±11.0 <0.01
Heart failure, n (%) 4 (7%) 10 (16%) 3 (11%) 10 (18%) NS
GLS (%) −16.2±4.2 −14.7±4.5 −15.5±3.2 −15.1±4.2 NS
TR max PG (mmHg) 26.2±10.9 30.7±11.0 29.3±10.2 31.9±13.2 NS
Valvular disease, n (%) 14 (23) 23 (34) 19 (37) 26 (44) <0.05
Values expressed in numbers (percentage), mean± standard deviation (SD) or median (interquartile range (IQR)). FGF23=ﬁbroblast growth fac-
tor 23; ESRD=end stage renal disease; BP=blood pressure; PTH=parathyroid hormone; CRP=C-reactive protein; IVSd= interventricular septum
end diastolic diameter; LVPWd= left ventricular posterior wall end diastolic diameter; LVIDd= left ventricular internal end diastolic diame-
ter; LV= left ventricle; LVPWd= left ventricular posterior wall end diastolic diameter; LVH= left ventricular hypertrophy, LAEDV= left atrium
ion fr
Hyperphosphataemia due to reduced renal clearance
is almost universal in ESRD. Hyperphosphatemia is anend diastolic volume; MV=mitral valve; LVEF= left ventricular eject
PG=peak gradient. *See Table 1
Correlations to LVMI and LVEF are shown in Table 4.
Independent correlations to LVMI were presence of cardiac
arrhythmia, peripheral vascular disease and p-phosphate.
While log FGF23 was highly correlated with LVMI on a uni-
variate analysis, it was only marginally signiﬁcant on the
multivariate analysis (r=0.13, p=0.05), and only if arrhythmia
and peripheral vascular disease were forced out of the model.
A post hoc multivariate analysis of LVM however showed an
independent effect of FGF23. (r=0.16, p<0.05). In contrast,
phosphate was not correlated with LVEF on univariate and
multivariate analyses. The independent correlates were age,
log FGF23 and -blocker treatment.
Changes in variables during dialysis were correlated with
FGF23. Only two echocardiographic variables were signiﬁ-
cantly correlated with FGF23 during dialysis: change in LVM
(r=0.24, p<0.05) and LVEF (r=−0.15, p<0.05).action; GLS=global longitudinal strain; TR= tricuspid regurgitation;
Parathyroid hormone (PTH)was negatively related to LVIDd
(r=−0.14, p<0.05) and GLS (r=−0.18, p<0.05), but not to any
other echocardiographic variable.
Discussion
As previously reported,7 we found extremely elevated FGF23
levels in HD patients compared to levels in healthy subjects.
The prevalence of LVH in HD patients based on transthoracic
echocardiography ﬁndings was 46% and FGF23 was associated
to the presence and degree of LVH.important component of the disease complex called
Chronic Kidney Disease – Mineral Bone Disorder (CKD-MBD),
nefrolog ia 2019;39
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Fig. 1 – Correlation between log FGF23, Left ventricular
mass index (LVMI) and left ventricular ejection fraction
biplane (LVEF).
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haracterized by biochemical, bone and vascular disorders.
lements of this disease include hypercalcemia, hypocal-
aemia, hyperparathyroidism, osteitis ﬁbrosa, adynamic bone
isease, low 25-hydroxycholecalciferol (25-OHD), low 1,25-
ihydroxycolecalciferol (1,25-OHD), reduction of calciﬁcation
nhibitors, and vascular calciﬁcation. Hyperphosphatemia
an itself cause vascular deposition of calcium phosphate, but
ore importantly causes a phenotypic conversion of smooth
uscle cells to osteoblasts.46 Plasma phosphate is positively
orrelated with LVH.47–49
LVH and increased myocardial ﬁbrosis is primarily caused
y hypertension, chronic secondary hyperaldosteronism and
amage by unidentiﬁed uremic toxins. FGF23 also causes
VH5 independently of phosphate effects. FGF23 antagonist
reatment reduces LVH in rodents.50 The effect is both direct
nd secondary to volume overload secondary to sodium
etention18,51 and activation of the renin-angiotensin system
RAS).35,52
FGF23 is an element of CKD-MBD, and interacts with
,25-OHD and parathyroid hormone (PTH). FGF23 suppresses
TH production,53 which in turn stimulates FGF23.54 FGF23
uppresses renal production of 1,25-OHD,55 while 1,25-OHD(3):258–268 263
increases FGF23 production,56 attenuates FGF23/FGFR4 sig-
naling and LVH in uremic rats.36 Overall, FGF23 is positively
correlated with PTH in ESRD, presumably due to its suppres-
sive effects on 1,25-OHD and PTHs stimulatory effects. PTH
is also correlated with LVH in non-uremic subjects57–59 and
ESRD patients in one study, but not another.47,60 Vitamin D
appears to have a protective effect against LVH.61,62 Thus, it
is not clear which of these four factors are most important in
the development of LVH: phosphate, low 1,25-OHD or FGF23.
As discussed in the Introduction, controversy exists con-
cerning the relationship of FGF23 to cardiovascular disease in
ESRD. The present paper presents the largest study on this
subject, almost doubling the available data. We found signiﬁ-
cant relationships between FGF23 and LVMI, LVEF, mortality
and cardiovascular events. This is the ﬁrst study reporting
a negative relationship between LVEF and FGF23 in ESRD
patients. This is perhaps surprising, since continuing LVH
leads to maladaptive cardiomyocytes changes, cardiomy-
ocytes death and myocardial ﬁbrosis,63 and eventually to
systolic dysfunction, as illustrated in Fig. 2. However, when
employing multivariate analysis, the correlation to cardiovas-
cular events disappeared. LVMI was mainly correlated with
phosphate; after correction for this, the effect of FGF23 was
marginal. LVMI and LVEF were not correlated with dialysis
duration, suggesting that the correlations are not due to tem-
poral factors. As the study was a cross-sectional study, any
discussion of causationmust be speculative and there is risk of
confounding regarding the interpretation of the ﬁndings in the
study. However, the lack of correlation of PTH to most of these
variables suggest that this is not an important factor, and that
previous correlations are mainly due to indirect effects, e.g.
via FGF23 stimulation. Similarly, phosphate does not appear
to have a pathogenic role in LVEF, but seems to be important
to LVMI. Vitamin D was not evaluated in this study.
Other variables were also included in the investigation.
As previously discussed, FGF23 is implicated in the devel-
opment of vascular calciﬁcation. In this study, FGF23 was
not related to pulse pressure, used as a marker of vascular
calciﬁcation, but was associated with presence of valvular
abnormalities (as valvular sclerosis), anothermarker of vascu-
lar calciﬁcation. Not surprisingly, echocardiographic variables
were highly correlated with cardiovascular events, and LAEDV
index and GLS, an advanced Doppler measure of LV’s systolic
function, remained signiﬁcant in the multivariate analysis.
The contractile function of the left atrium is important for
cardiac function, in particular in patients with reduced LVEF,
and reduced LAEDV is predictive of atrial ﬁbrillation, cere-
brovascular events, acute coronary syndromes, heart failure
and mortality in non-uremic subjects.64 Increased LAEDV is
correlated with death both in HD65 and PD66 patients. This
study conﬁrms these ﬁndings. Since FGF23 was correlated
with LAEDV, it may also play a role in this problem. Finally
FGF23 is predictive of atrial ﬁbrillation innon-uremic,12 CKD,67
and ESRD37 patients; we were unable to conﬁrm this ﬁnding.This study is a cross-sectional study, with all the limitations
that such a study entails. In particular, any discussion of
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Table 3 – Correlations to mortality and cardiovascular events. Relative risk (conﬁdence interval). Signiﬁcant variables
only. Pearson correlation analysis.
Variable Mortality risk Cardiovascular event risk
Univariate Multivariate Univariate Multivariate
Clinical
Age (decade) 1.61 (1.34–1.95)c 1.65 (1.35–2.02)c 1.20 (0.99–1.44)
Diabetes 2.74 (1.67–4.51)c
Previous cancer 1.56 (1.00–2.42)a
Ischemic heart disease 1.60 (1.05–2.44)a 3.26 (1.98–5.37)c
Previous AMI 2.89 (1.71–4.90)c
NYHA Class 1.70 (1.31–2.21)c 1.59 (1.17–2.15)b
Diastolic BP (mmHg) 0.975 (0.96–0.99)b
Biochemical
Ferritin (mg/L) 1.77 (1.12–2.78)a 1.74 (1.04–2.91)a
Transferrin (mM) 0.95 (0.90–1.00)a
Albumin (g/L) 0.93 (0.89–0.97)c
Creatinine (mM) 0.22 (0.09–0.56)b 0.21 (0.08–0.60)b
CRP (mg/L) 1.009 (1.005–1.014)c
Logn CRP (mg/L) 1.49 (1.26–1.77)c 1.49 (1.26–1.77)c 1.25 (1.01–1.53)a 1.43 (1.06–1.92)b
Logn FGF23 (RU/ml) 1.24 (1.04–1.47)a 1.47 (1.22–1.77)c
Echocardiography
LVPWd (cm) 16.7 (3.6–77.1)c
LVM (g) 1.008 (1.003–1.012)c
LVM index (g/m2) 1.012 (1.004–1.021)b
LVH 2.12 (1.27–3.54)b
LAEDV Index (ml/m2) 1.03 (1.02–1.05)c 1.04 (1.02–1.06)b
LVEF biplane (%) 0.97 (0.95–0.99)b
GLS (%) 1.17 (1.09–1.26)c 1.15 (1.06–1.27)c
Heart failure 2.16 (1.21–3.86)b
Valvular disease 1.73 (1.05–2.85)a
a p<0.05.
b p<0.01.
c p<0.001. AMI=acute myocardial infarction; NYHA=New York Heart Association; BP=blood pressure; CRP=C-reactive protein;
FGF23=ﬁbroblast growth factor 23; LVPWd= left ventricular posteriorwall end diastolic diameter; LVIDd= left ventricular internal end diastolic
diameter; LV= left ventricle; LVPWd= left ventricular posterior wall end
hypertrophy, LAEDV= left atrium end diastolic volume; LVEF= left ventriFig. 3 – Patient survival plot according to FGF23 quartiles.possible causative mechanisms must be speculative. Our
result showed a signiﬁcant correlation between reduced LVEF
and FGF23 which is a new ﬁnding but a pathological mecha-
nism is not yet clear. Therefore further investigations betweendiastolic diameter; LVM= left ventricular mass; LVH= left ventricular
cular ejection fraction; GLS=global longitudinal strain.
systolic function of left ventricle and FGF23 and its recep-
tors in myocardial cells should clarify possible mechanisms.
Our study was designed to evaluate LVH, ejection fraction and
FGF23 in a large hemodialysis population, but for minimiz-
ing possible confounders a prospective cohort study could be
a better option for a future study design, thereby looking at
the level of FGF23 and the process in developing LVH in HD
patients.
For acquisition and interpretation of the transthoracic
echocardiography there were used three echocardiographers,
which had the same amount of training and were trained at
the same echocardiography laboratory to minimize any bias.
Both acquisition and interpretation were done blinded for the
study results.
Our study did consider the effect of dialysis duration
on our ﬁndings, and showed no correlation between our
echocardiography results and the duration of HD. But for a
better understanding of ﬂuid removal and volume overload
on echocardiography ﬁndings it could have an impact on these
results if corrected for accumulated time in hemodialysis per
week or Kt/V, which we did not investigate in our study. It
would also be of interest to investigate the effect of sodium
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Table 4 – Regression correlations to left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF).
Pearson correlation R values. Signiﬁcant variables only.
Variable LVMI LVEF
Univariate Multivariate* Univariate Multivariate*
Clinical
Age −0.16b −0.16b
Diabetes 0.13a
Diuresis −0.21b
Peripheral vascular disease 0.16a 0.17b
Hypertension 0.20b 0.15a
Arrhythmia 0.19b 0.21c −0.28c
Pulse (bpm) −0.22c
O2 Saturation (%) 0.19b
Heart failure 0.25c −0.27c
NYHA Class −0.20b
Dialysis ultraﬁltration 0.27c −0.18b
Medication
Diuretic 0.16a
-blocker 0.18b 0.18b 0.20b
RAAS blockade 0.18b
Calcium antagonist 0.19b
-blocker 0.14a
Minoxidil 0.16a
Biochemical
Creatinine (M) 0.15a
Logn CRP (mg/L) −0.14a
Phosphate (mM) 0.25c 0.20c
Logn FGF23 (RU/ml) 0.21c −0.17b −0.21c
Echocardiography
IVSd (cm) 0.44c
LVIDd (cm) 0.66c −0.33c
LVIDd index (cm/m2) 0.66c −0.27c
LV dilatation 0.40c −0.15a
LVPWd (cm) 0.49c −0.26c
LVM (g) NI −0.29c
LVM Index (g/m2) NI −0.29c
LVH NI −0.27c
LAEDV Index (ml/m2) 0.43c −0.37c
LVEF biplane (%) −0.29c NI
MV E/A 0.28c −0.27c
MV E/é 0.14a −0.17a
GLS (%) 0.29c −0.51c
TR maxPG (mmHg) 0.21b −0.22b
a p<0.05.
b p<0.01.
c p<0.001.
∗ Echocardiography variables not included. NI =not included; NYHA=New York Heart Association; RAAS= renin-angiotensin-aldosterone sys-
tem;CRP=C-reactive protein; FGF23=ﬁbroblast growth factor 23; IVSd= interventricular septumenddiastolic diameter; LVIDd= left ventricular
internal end diastolic diameter index; LV= left ventricle; LVPWd= left ventricular posterior wall end diastolic diameter; LVM= left ventricular
iasto
inal s
a
ﬁ
d
e
p
i
b
cmass; LVH= left ventricular hypertrophy; LAEDV= left atrium end d
valve E/A ratio; MV E/é=mitral valve E/é ratio; GLS=global longitud
nd volume overload, but unfortunately sodium was not suf-
cient for our study. Almost all included patients had three
ays in HD per week and mostly during weekdays, with week-
nds without undergoing HD therapy. In the study almost all
atients were included on weekdays.
Due to removal of patient ﬁles, some information concern-
ng CKD-MBD therapy was deﬁcient and could therefore not
e investigated further. It is possible that drugs in CKD-MBD
ould have an effect on the results presented in the study.lic volume; LVEF= left ventricular ejection fraction; MV E/A=mitral
train; TR max PG= tricuspid regurgitation max peak gradient.
Conclusion
FGF23 levels were extremely high in HD patients compared
to levels in healthy subjects. The prevalence of LVH in HD
patients was 46% and echocardiographic HFrEF, deﬁned by
LVEF <40%, was 12%. FGF23 was associated to LVH as well as
reduced LVEF. FGF23 predicted overall mortality but not car-
diovascular events.
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